Can a diabetes drug and a salt compound boost exercise in heart failure?

NCT ID NCT05138575

Recruiting now Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin (a diabetes drug) and potassium nitrate (a supplement) can improve exercise endurance in people with heart failure with preserved ejection fraction (HFpEF). About 53 participants will take one of three combinations of these drugs for a period, then undergo exercise tests to measure how long they can walk or cycle. The goal is to see if these treatments help muscles work better and improve daily stamina.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (Jardiance) and Potassium Nitrate (KNO3)
What this could lead to: If successful, this could point toward a treatment that helps people with heart failure exercise longer and feel better day-to-day.
What could go wrong: This is a small, early-phase trial with only 53 participants, so results may not apply to everyone. The drugs may not improve endurance as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Locations

University of Pennsylvania Health System
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.